| DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program |
Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI , May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO. |
prnewswire.com |
2025-05-09 12:22:00 |
Czytaj oryginał (ang.) |
| InMode to Present at Upcoming Investor Conferences and Events |
YOKNEAM, Israel , May 7, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation can be accessed here. |
prnewswire.com |
2025-05-07 12:30:00 |
Czytaj oryginał (ang.) |
| InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges |
IRVINE, Calif. , May 6, 2025 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2025-05-06 12:03:00 |
Czytaj oryginał (ang.) |
| InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade) |
InMode's Q1 2025 results disappointed, with revenue and EPS missing estimates, leading to a 12% stock drop and another potential guidance cut. Despite solid fundamentals and attractive valuation, weakening demand, no buybacks, and uncertain forecasts make me downgrade INMD from Buy to Hold. The company has high margins, lots of cash, and operates in a growing market, but short-term catalysts are lacking. |
seekingalpha.com |
2025-04-29 11:00:51 |
Czytaj oryginał (ang.) |
| InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade) |
InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects. |
seekingalpha.com |
2025-04-29 05:52:07 |
Czytaj oryginał (ang.) |
| Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City |
New York, New York--(Newsfile Corp. - April 28, 2025) - Eyes On Park, a leading optometry practice in Gramercy Park, announces the introduction of the cutting-edge Envision by InMode system for comprehensive dry eye treatment. Dr. Irina Shiyan and her team now offer this advanced, non-invasive technology that combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, not just the symptoms. |
newsfilecorp.com |
2025-04-28 17:41:00 |
Czytaj oryginał (ang.) |
| InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript |
InMode Ltd. (NASDAQ:INMD ) Q1 2025 Earnings Conference Call April 28, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - CEO Yair Malca - CFO Conference Call Participants Matt Miksic - Barclays Danielle Antalffy - UBS Matt Taylor - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Sam Eiber - BTIG Dane Reinhardt - Baird Operator Good day, and welcome to InMode's First Quarter 2025 Earnings Results Conference Call. |
seekingalpha.com |
2025-04-28 15:53:48 |
Czytaj oryginał (ang.) |
| InMode (INMD) Lags Q1 Earnings Estimates |
InMode (INMD) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.45 per share a year ago. |
zacks.com |
2025-04-28 13:25:32 |
Czytaj oryginał (ang.) |
| InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease |
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. |
prnewswire.com |
2025-04-28 11:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline |
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-21 15:05:52 |
Czytaj oryginał (ang.) |
| InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock? |
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-10 16:40:52 |
Czytaj oryginał (ang.) |
| InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade) |
I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels. |
seekingalpha.com |
2025-04-03 08:26:50 |
Czytaj oryginał (ang.) |
| 3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally |
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD. |
zacks.com |
2025-03-26 14:45:38 |
Czytaj oryginał (ang.) |
| InMode to Present at the 24th Annual Needham Virtual Healthcare Conference |
YOKNEAM, Israel , March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. |
prnewswire.com |
2025-03-26 10:30:00 |
Czytaj oryginał (ang.) |
| Is InMode (INMD) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-03-25 12:40:29 |
Czytaj oryginał (ang.) |
| InMode Responds to Doma Perpetual's Letters |
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel , March 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025. |
prnewswire.com |
2025-03-06 09:30:00 |
Czytaj oryginał (ang.) |
| InMode to Present at Upcoming Investor Conferences |
YOKNEAM, Israel , March 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 27th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings Location: Miami, FL When: Wednesday, March 12 at 9:00 am EDT A live webcast of the presentation can be accessed here. |
prnewswire.com |
2025-03-03 10:30:00 |
Czytaj oryginał (ang.) |
| InMode: Plastic Surgery Boom, Cash Flow, And Cheap |
InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability. |
seekingalpha.com |
2025-02-10 03:14:35 |
Czytaj oryginał (ang.) |
| InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript |
InMode Ltd. (NASDAQ:INMD ) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Danielle Antalffy - UBS Matt Miksic - Barclays Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Sam Eiber - BTIG Operator Good day, and welcome to the InMode Fourth Quarter and Full Year 2024 Earnings Results Conference Call. |
seekingalpha.com |
2025-02-06 11:08:06 |
Czytaj oryginał (ang.) |
| InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program |
Quarterly GAAP revenues of $ 97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. |
prnewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference |
YOKNEAM, Israel , Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT on Wednesday, February 12, 2025. |
prnewswire.com |
2025-02-03 10:30:00 |
Czytaj oryginał (ang.) |
| InMode: A Clear Bargain With Unique Risks |
InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks. |
seekingalpha.com |
2025-01-28 11:32:02 |
Czytaj oryginał (ang.) |
| InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced |
Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2025-01-16 09:00:00 |
Czytaj oryginał (ang.) |
| DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback |
Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action MIAMI , Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase. |
prnewswire.com |
2025-01-15 10:05:00 |
Czytaj oryginał (ang.) |
| InMode: Clearly, I Was Too Optimistic (Rating Downgrade) |
I'm downgrading InMode from a 'Strong Buy' to a 'Buy' due to consistent guidance cuts and short-term demand issues. Despite recent performance issues and high interest rates, INMD still holds a strong cash position, has high margins, and offers a good long-term entry point with a solid earnings yield. The company's revenue forecasts for 2024 and 2025 have been lowered notably, indicating potential market saturation and weak demand. |
seekingalpha.com |
2025-01-10 08:07:31 |
Czytaj oryginał (ang.) |
| InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M |
Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| InMode: Product Origination And Undervaluation Make The Stock A Buy |
InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and significant cash flow, with minimal liabilities, indicating a robust financial position and undervaluation. |
seekingalpha.com |
2024-12-12 03:17:21 |
Czytaj oryginał (ang.) |
| InMode to Present at Upcoming Investor Conferences |
YOKNEAM, Israel , Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in November and December: UBS Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetings Location: Palos Verdes, CA When: Tuesday, Nov. 12 at 2:00 pm PT A live webcast of the presentation can be accessed here. |
prnewswire.com |
2024-11-06 10:30:00 |
Czytaj oryginał (ang.) |
| InMode: $25/Share Is Closer Than You Think |
Elevated interest rates continue to hurt InMode's revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war. |
seekingalpha.com |
2024-11-05 11:43:32 |
Czytaj oryginał (ang.) |
| InMode: A Deep Dive After Q3 Earnings |
InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to see value in their products. |
seekingalpha.com |
2024-10-31 14:16:51 |
Czytaj oryginał (ang.) |
| InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript |
InMode Ltd. (NASDAQ:INMD ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Conference Call Participants Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Sam Eiber - BTIG Operator Good day, and welcome to the InMode's Third Quarter 2024 Earnings Results Conference Call. |
seekingalpha.com |
2024-10-30 13:33:11 |
Czytaj oryginał (ang.) |
| InMode (INMD) Q3 Earnings and Revenues Beat Estimates |
InMode (INMD) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago. |
zacks.com |
2024-10-30 11:16:25 |
Czytaj oryginał (ang.) |
| InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024) |
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024. |
prnewswire.com |
2024-10-30 09:00:00 |
Czytaj oryginał (ang.) |
| Pomerantz Law Firm Announces Filing Deadline in Class Action Against InMode Ltd. and Certain Officers – INMD |
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Pomerantz LLP hereby advises investors of recent developments in the class action lawsuit Cement Masons' and Plasterers' Local No. 502 Pension Fund v. |
accesswire.com |
2024-10-28 18:15:00 |
Czytaj oryginał (ang.) |
| InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories |
IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2024-10-24 11:03:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: InMode (INMD) Q3 Earnings Expected to Decline |
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-23 15:07:54 |
Czytaj oryginał (ang.) |
| Is InMode (INMD) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-10-14 14:50:08 |
Czytaj oryginał (ang.) |
| InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024 |
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2024-10-10 11:00:00 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's September 2024 New Analysts |
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies. |
seekingalpha.com |
2024-10-04 12:00:00 |
Czytaj oryginał (ang.) |
| InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy |
YOKNEAM, Israel , Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024. |
prnewswire.com |
2024-10-01 11:00:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy InMode (INMD) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-09-26 14:46:29 |
Czytaj oryginał (ang.) |
| InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade) |
InMode's Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs. |
seekingalpha.com |
2024-09-19 11:14:40 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing InMode (INMD) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-09-10 14:46:22 |
Czytaj oryginał (ang.) |
| InMode Announces Share Repurchase Program of Up to 7.68 Million Shares |
YOKNEAM, Israel , Sept. 10, 2024 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2024-09-10 11:00:00 |
Czytaj oryginał (ang.) |
| InMode Stock: An Inverse Bubble Caused By Short-Term Trouble |
InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook. |
seekingalpha.com |
2024-09-06 08:38:52 |
Czytaj oryginał (ang.) |
| InMode to Present at 2024 Baird Global Healthcare Conference |
YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd. |
prnewswire.com |
2024-09-04 12:30:00 |
Czytaj oryginał (ang.) |